Misplaced Pages

Povorcitinib

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound

Pharmaceutical compound
Povorcitinib
Clinical data
Other namesINCB-054707
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • 4-azetidin-1-yl]-2,5-difluoro-N-benzamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC23H22F5N7O
Molar mass507.469 g·mol
3D model (JSmol)
SMILES
  • CC1=C(C(=NN1)C)C2=CN(N=C2)C3(CN(C3)C4=C(C=C(C(=C4)F)C(=O)N(C)C(F)(F)F)F)CC#N
InChI
  • InChI=1S/C23H22F5N7O/c1-12-20(13(2)33-32-12)15-8-30-35(9-15)22(4-5-29)10-34(11-22)19-7-17(24)16(6-18(19)25)21(36)31-14(3)23(26,27)28/h6-9,14H,4,10-11H2,1-3H3,(H,31,36)(H,32,33)/t14-/m0/s1
  • Key:MSGYSFWCPOBHEV-AWEZNQCLSA-N

Povorcitinib is an investigational new drug that is being evaluated for the treatment of the skin conditions hidradenitis suppurativa and chronic prurigo. It is a JAK1 inhibitor.

References

  1. Alavi A, Hamzavi I, Brown K, Santos LL, Zhu Z, Liu H, Howell MD, Kirby JS. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies. Br J Dermatol. 2022 May;186(5):803-813. doi:10.1111/bjd.20969 PMID 34978076
  2. Kirby JS, Okun MM, Alavi A, Bechara FG, Zouboulis CC, Brown K, Santos LL, Wang A, Bibeau KB, Kimball AB, Porter ML. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. J Am Acad Dermatol. 2024 Mar;90(3):521-529. doi:10.1016/j.jaad.2023.10.034 PMID 37871805
  3. "Povorcitinib - Incyte Corporation". AdisInsight. Springer Nature Switzerland AG.
  4. Thünemann J, Müller S, Steinbrink K, Ständer S, Zeidler C (June 2024). "Chronic Prurigo". Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology: JDDG. 22 (6): 813–823. doi:10.1111/ddg.15317. PMID 38722190.
  5. Liao V, Cornman HL, Ma E, Kwatra SG (May 2024). "Prurigo nodularis: new insights into pathogenesis and novel therapeutics". The British Journal of Dermatology. 190 (6): 798–810. doi:10.1093/bjd/ljae052. PMC 11099982. PMID 38345154.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: